A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

Updated on 10 May 2022
ovarian cancer
metastatic cervical cancer
urothelial carcinoma


The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts.

  • Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. 
  • Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.



Contact Incyte Corporation Call Center (US):

  • 1.855.463.3463
  • medinfo@incyte.com
  • Details
    Condition SCLC, Melanoma, Colorectal Cancer, SCCHN, Ovarian Cancer, Mesothelioma, Small Cell Lung Cancer, DLBCL, Gastric Cancer, Urothelial Carcinoma, Esophageal Cancer, Hepatocellularcarcinoma, Merkel Cell Carcinoma, Endometrial Cancer, Breast Cancer, NSCLC, Cervical Cancer, RCC
    Clinical Study IdentifierTX218245
    Last Modified on10 May 2022


    Yes No Not Sure

    Inclusion Criteria

    Years and older
    Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent
    Disease progression after treatment with available therapies that are known to confer clinical benefit, or intolerant to treatment, or refuse noncurative standard treatment. There is no limit to the number of prior treatment regimens
    Participants with advanced or metastatic cervical cancer, MSI-high endometrial cancer, gastric cancer (including stomach and GEJ), esophageal cancer, hepatocellular carcinoma, melanoma (uveal melanoma excluded), Merkel cell carcinoma, mesothelioma, MSI-high colorectal cancer, NSCLC, ovarian cancer, SCCHN, SCLC, RCC, triple-negative breast cancer, and urothelial carcinoma, or alternative immunogenic tumor types with medical monitor approval. Participants with DLBCL may participate in Part 2 of the study
    Presence of measureable disease based on RECIST v1.1 for solid tumors or the Lugano classification for DLBCL
    Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies
    Eastern Cooperative Oncology Group performance status 0 or 1

    Exclusion Criteria

    Laboratory and medical history parameters outside the protocol-defined range
    Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before study Day 1
    Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
    Receipt of a live vaccine within 30 days of planned start of study drug
    Active autoimmune disease that required systemic treatment in the past
    Known active CNS metastases and/or carcinomatous meningitis
    Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry. See protocol-defined exceptions
    Evidence of active, noninfectious pneumonitis or history of interstitial lung disease
    Active infection requiring systemic therapy
    Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation
    Known history of HIV (HIV 1/2 antibodies)
    Prior treatment with an anti-LAG-3 antibody for any indication
    Clear my responses

    How to participate?

    Step 1 Connect with a study center
    What happens next?
    • You can expect the study team to contact you via email or phone in the next few days.
    • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

    You are contacting

    Investigator Avatar

    Primary Contact


    Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

    Learn more

    If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

    Learn more

    Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

    Learn more

    Similar trials to consider


    Browse trials for

    Not finding what you're looking for?

    Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

    Sign up as volunteer

    user name

    Added by • 



    Reply by • Private

    Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

      The passcode will expire in None.

    No annotations made yet

    Add a private note
    • abc Select a piece of text from the left.
    • Add notes visible only to you.
    • Send it to people through a passcode protected link.
    Add a private note